Cryoport Systems achieved ISO 21973:2020 certification, the first in the industry, confirming compliance with the international standard that governs environmental control, equipment, processes, logistics, and information for transporting therapeutic cells.
The certification, awarded on October 30, 2025, reduces the risk of temperature excursions, contamination, and chain‑of‑custody breaches, thereby protecting the viability of life‑changing treatments.
Cryoport had previously helped develop the ISO 21973 standard and earned the 2025 CPHI Award for Supply Chain Excellence for its integrated platform, announced on October 29, 2025.
In its most recent quarterly report, Cryoport reported a 14% year‑over‑year increase in total revenue to $45.5 million for Q2 2025, with Life Sciences Services revenue up 21% year‑over‑year to $24.4 million (54% of total revenue). The company reaffirmed its full‑year 2025 revenue guidance of $165 million to $172 million.
The ISO certification strengthens Cryoport’s position as a leader in regenerative medicine logistics and supports its strategic focus on high‑growth life sciences services, including expansion into reproductive medicine and animal health.
Management highlighted that the certification will enhance customer confidence and open new opportunities in the rapidly growing cell and gene therapy market, while noting that the company continues to invest in its integrated platform and partnership with DHL Group to improve operational efficiency.
Cryoport’s divestiture of its CRYOPDP business and ongoing focus on profitability and positive adjusted EBITDA underscore its commitment to delivering reliable, high‑quality logistics solutions for the life sciences sector.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.